GlaxoSmithKline (GSK) announces CSO Dr Hal Barron to step to a Non-Executive Director role.

– UK, Brentford – GlaxoSmithKline plc (LON: GSK) today announced the appointment of Tony Wood as CSO designate to succeed Dr. Hal Barron, on 1 August 2022, after which Dr. Hal Barron will remain on the Board as a Non-Executive Director.

About Tony Wood

Tony Wood is a highly respected scientist and one of the world’s pre-eminent chemists, with more than 30 years of experience working across diverse disciplines of R&D to deliver innovative medicines. He joined GSK from Pfizer in 2017, as Senior Vice President, Medicinal Science, and Technology, and is responsible for all science and technology platforms supporting the discovery, clinical development, and delivery of new medicines across GSK.

During his career, Tony has led large-scale global organizations in drug discovery and development in multiple therapeutic areas, including immunology, oncology, and infectious diseases. He has been pivotally involved in the launch of many new medicines at GSK, including Nucala, Blenrep, Jemperli, Cabenuva, and most recently Xevudy. Tony has also been integral to delivering the recent improvements in GSK’s R&D productivity and central to developing its R&D approach focusing on the science of the immune system, human genetics, and advanced technologies, notably building capabilities in functional genomics, artificial intelligence, and machine learning.

Tony Wood will assume full accountability for R&D across GSK’s portfolio and pipeline from August 2022. After this, Hal will remain a member of GSK’s Board transitioning to serve as a Non-Executive Director and a member of the Board’s Science Committee for an initial period of three years. In addition to his Non-Executive responsibilities, Hal will also provide advice and support on scientific and asset development matters and will attend key R&D executive investment and advisory committees. He will also continue to engage with the scientific community, R&D partners, and other companies, as required, in support of R&D and on behalf of GSK.

As announced by Altos Labs today, Hal will assume the position of CEO and Board Co-Chair of Altos Labs effective 1 August 2022. Altos Labs is a new, private biotechnology company based in the San Francisco Bay Area, with multiple global sites, and is focused on the biology of cellular rejuvenation programming to reverse disease.

Emma Walmsley, CEO said: “We are delighted to appoint Tony as our next CSO. He is an outstanding scientist who is highly respected inside and outside GSK. Tony has been a key partner to Hal in delivering our R&D approach, and with his experience and expertise across science, data, and new technologies, he is perfectly placed to build on Hal’s outstanding progress and to deliver value from our pipeline. Hal’s appointment to Altos Labs is a unique opportunity for him and we are pleased that GSK will continue to benefit from his expertise at the Board and in support of R&D. Altogether, these changes provide us with a clear pathway for continued momentum in R&D to deliver our new ambitions for growth and scale impact for patients.”

Hal Barron, CSO said: “Tony will be an outstanding Chief Scientific Officer for GSK. I have worked closely with him for several years. I know him as a person and scientist of the highest quality. In the last four years, we have significantly improved the quality and strength of the pipeline and our overall R&D productivity, delivering 13 major product approvals and more than doubling the number of assets in Phase III/registration to 23. GSK now has a pipeline of 21 vaccines and 42 medicines – many of which offer potential best or first-in-class opportunities for patients and will drive growth at GSK well into the next decade. I’m very excited to remain part of GSK and to play a significant role within the company as I transition to a Non-Executive Board member and support Tony and the team to deliver on the promise of our pipeline.”

Tony Wood, Chief Scientific Officer designate said: “I am honoured to have been asked to lead GSK’s R&D. In the past few years, under Hal’s leadership, we have made enormous progress to strengthen the pipeline and put in place an R&D approach that can improve the efficiency and success of medicine and vaccine development. With the progress already made, and together with the many talented people we have working in our R&D organisation, I am confident that we will deliver highly successful and much needed scientific innovation for patients in the years ahead.”

About GSK

GSK is a science-led global healthcare company.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.